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ABSTRACT
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused 
by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient 
subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety 
of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC 
patients, and to evaluate sustained virological response (SVR) indicators and early treatment 
interruption due to serious adverse events (SAE). This was a retrospective observational study 
of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine 
Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) 
were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-
infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), 
respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted 
treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% 
CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 
0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 
1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-
3.83; p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, 
mainly in young patients without advanced liver disease or when the use of direct-action 
drugs is limited to specific patient groups.
KEYWORDS: Hepatitis C. Chronic hepatitis C. Coinfection HCV-HIV. Interferons. 
Ribavirin. HCV genotypes.
INTRODUCTION
Hepatitis C virus (HCV) infects 185 million people worldwide1. The HCV 
genotype 3 (GEN3) represents the second most common genotype, corresponding 
to 30% of infection cases1. The prevalence of patients with GEN3 in Brazil2 and 
in tropical Latin America1 is among the highest in the world. This genotype is also 
the most frequent among injectable drug users and often occurs in individuals 
who are co-infected by HIV3. Different studies suggest that GEN3 is associated 
with the more aggressive forms of hepatic disease, including hepatic cirrhosis and 
hepatocellular carcinoma4.
The use of pegylated interferon (Peg-IFN) in combination with ribavirin (RBV) 
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was until recently the therapy of choice for patients with 
chronic hepatitis C (CHC)5. However, the development 
of direct-action antiviral (DAA) agents improved the 
rates of success in the treatment of HCV, especially HCV 
genotype 1, both in mono- and co-infected patients5-7. In 
different regions of the world, DAAs have also become the 
main line of action against GEN3/CHC8. However, cirrhotic 
patients infected with GEN3 do not respond as well to this 
new drug generation4,5,7,9. Moreover, the universal use of 
these drugs is limited by their high cost8.
The analysis of real-life patient cohorts treated with 
Peg-IFN/RBV may yield important information for future 
decision making based on the effectiveness and safety of 
new drugs, if compared with the classic standard therapy. 
Knowledge of patient groups at higher probability for 
therapeutic success and at lower risk of interruption due to 
serious adverse events (SAE) may support the inclusion of 
classic therapy as a viable alternative in specific contexts. 
The present study aimed at evaluating the effectiveness 
and safety of the Peg-IFN/RBV combination treatment 
for patients with GEN3/CHC, with or without HIV 
co-infection, in a real-life context. It has also assessed what 
factors may better predict a SVR and the early treatment 
interruption due to SAE. 
MATERIAL AND METHODS
Study design and patient selection
We conducted an observational, retrospective and 
multicentric study with non-probability sampling that 
has investigated the disease outcome in patients infected 
by HCV/GEN3, with or without HIV co-infection, and 
treated with Peg-IFN/RBV in a real-life context between 
January 2005 and October 2010, in nine secondary or 
tertiary healthcare reference centers in Brazil, as follows: 
Departamento de Doenças Infecciosas e Parasitárias da 
Faculdade de Medicina da Universidade de São Paulo 
(USP), São Paulo; Departamento de Gastroenterologia e 
Hepatologia da Faculdade de Medicina da Universidade 
de São Paulo (USP), São Paulo; Universidade Federal de 
São Paulo (UNIFESP), São Paulo; Centro de Referência e 
Tratamento DST-AIDS de São Paulo; Universidade Federal 
do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro; 
Universidade Federal do Espírito Santo (UFES), Vitória; 
Faculdade de Medicina da Universidade de São Paulo, 
Ribeirão Preto; Instituto de Infectologia Emilio Ribas, 
São Paulo; Unidade Mista de Saúde – Unimista, Brasília.
All patients admitted in these centers were included and 
received a minimum of one dose of Peg-IFN during the 
treatment regimen of 24 to 48 weeks. Treatment regimens 
were conducted in accordance with the guidelines defined 
by the Brazilian Health Ministry, following international 
recommendations. 
Patients were included when they met the following 
criteria: being 18 years old or older; having infection by 
HCV/GEN3 confirmed through a molecular biology test for 
the detection or quantification of viral RNA (HCV RNA); 
having taken at least one dose of Peg-IFN, in any form 
available, including Peg-IFN alpha 2a (Pesagys, Roche) or 
Peg-IFN alpha 2b (Pegintron, MSD), in combination with 
RBV. The HIV infection diagnosis followed the criteria 
defined by the Brazilian Health Ministry10. Patients with 
hepatitis B virus co-infection or who had previously used 
Peg-IFN were excluded from the study. The study was 
approved by the Research Ethics Committee on Humans 
of all centers involved in the research and, given its 
retrospective nature, we were not able to collect informed 
consent from all study participants. Data were obtained by 
assessing the patients’ records as authorized by the Ethics 
Committee for Analysis of Research Projects from each of 
the involved medical centers.
Evaluation of effectiveness
The sustained virologic response (SVR) provided a 
measure of effectiveness. A patient was considered to have 
SVR when HCV RNA could not be detected (<50 UI/mL) 
by the ultrasensitive PCR method11, 24 weeks after the end 
of treatment with Peg-IFN/RBV. All patients admitted in 
these centers were included and received a minimum of 
one dose of Peg-IFN during the treatment regimen of 24 
to 48 weeks.
Among patients who did not experience SVR, other 
types of response were evaluated, depending on viral 
kinetics, defined as: 1) viral relapse (HCV RNA was 
undetectable at the end of treatment, but detectable at the 
24-week follow-up); 2) viral escape (undetectable HCV 
RNA during treatment followed by appearance of HCV 
RNA, despite continued treatment); 3) no response (HCV 
RNA level less than 2 log10 decline between baseline and 
week 12 or HCV RNA detectable at the end of treatment).
Safety evaluation
We evaluated and described the causes for early 
treatment interruption associated with SAE due to Peg-IFN/
RBV. The causes included hematological, cutaneous, and 
psychiatric alterations, infections, hepatic decompensation, 
drug intolerance, drug unavailability, decompensation of 
other comorbidities. SAE included all events that resulted 
in early treatment interruption. Moreover, treatment 
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intolerance was defined as the presence of non-specific 
symptoms such as inappetence, irritability, weight loss-
and a general sensation of discomfort that led to treatment 
interruption. 
Other forms of interruption were also evaluated such as 
non-adhesion or treatment abandonment. 
Analyzed variables
The variables selected for analysis were grouped into 
several categories: 1) demographic variables and status of the 
metabolic syndrome; 2) variables related to HCV infection 
(last registered alanine aminotransferase test results (ALT) 
prior to treatment; pattern of liver fibrosis and the occurrence 
of hepatic steatosis); 3) variables related to HCV treatment 
(history of treatment with conventional interferon, type 
of Peg-IFN used, duration and dose of RBV use, HCV 
RNA detection during treatment at weeks 12 and 24, and 
24 after the beginning of treatment, occurrence and causes 
for early treatment interruption). Patients were considered 
to have metabolic syndrome if they met three out of five 
criteria defined by the National Cholesterol Education 
Program, Adult Treatment Panel III12,13, including: 1) serum 
triglycerides above 150 mg/dL or use of triglyceride-control 
medication; 2) serum HDL below 40 mg/dL for men or 
50 mg/dL for women or use of medication for low HDL; 
3) arterial pressure above 130/85 mmHg or use of anti-
hypertensive medication; 4) plasma glucose above 110 mg/dL 
or use of hypoglycemic medication; 5) body mass index 
above 28.8 kg/m2 for men and women.
We defined the adequate RBV dose as the use of at 
least 800 mg/day. Normal alanine aminotransferase (ALT) 
values were defined as 31 U/L for women and up to 41 
U/L for men.
Data analysis
Data were analyzed by the STATA software version13.0 
(StataCorp LP, College Station, Texas, USA). The 
descriptive analyses of demographic, clinical, and 
therapeutic characteristics of CHC patients were reported 
as frequencies for qualitative variables and as estimate 
measures of central tendency and dispersion for quantitative 
variables. Contingency tables were used for the analysis of 
differences between mono-infected (HCV) and co-infected 
(HCV/HIV) patient groups through the Chi-square test (or 
Fisher exact-test) and through the unpaired Student’s t-test. 
Prevalence ratios (PRs) were estimated with their respective 
95% CI for the bivariate analysis of the relationship among 
several variables and the outcomes of interest: SVR and 
early treatment interruption due to SAE. A p-value below 
0.05 was considered statistically significant. 
Variables that, after bivariate analysis, experienced a 
p-value below 0.20 were selected for the multiple analysis 
using the Poisson regression with robust variance. However, 
we could not fit a multivariate model with statistical 
significance with the data obtained in this study.
RESULTS
The present study included 184 GEN3-infected 
individuals, among whom 114 (62%) were mono-infected 
and 70 (38%) were co-infected with HIV. Table 1 displays 
the main characteristics of the study population. 
Table 1 - Clinical and treatment variables of mono-infected patients with HCV and co-infected patients with HCV/HIV
Variable Mono-infected Co-infected P-value
Males, n/N (%) 62/114 (54) 49/70 (70) 0.036
Age, mean (SD) 50.5 (9.2) 44.5 (6.6) <0.001
ALT 2x/UNL, n/N (%) 61/114 (54) 31/67 (46) 0.347
Cirrhosisb, n/N (%) 35/114 (31) 14/65 (22) 0.186
Inflammatory activity 3 and 4c, n/N (%) 12/102 (12) 26/49 (53) <0.001
Liver steatosis, n/N (%) 57/99 (58) 27/49 (55) 0.775
Retreatment, n/N (%) 59/114 (52) 26/68 (38) 0.077
Current treatment, n/N (%) 0.312
Peg-IFN 2a 66/110 (60) 35/67 (52)
Peg-IFN 2b 44/110 (40) 32/67 (48)
Adequate initial dose of Ribavirind, n/N (%) 92/103 (89) 52/58 (90) 0.947
Adequate Ribavirin dose throughout the treatment, n/N (%) 83/103 (81) 6/11 (55) 0.061*
* Fischer exact test. a ALT 2x/UNL: alanine aminotransferase levels two-fold above the upper normal limit in the last test prior to the 
beginning of treatment. b Liver biopsy with Metavir fibrosis stage F4 or clinical manifestations of hepatic cirrhosis. c Inflammatory 
hepatic activity determined by liver biopsy and Metavir score. d At least 800mg/day
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Among the 184 included patients, 105 had SVR. Thus, 
the overall SVR rate was 57.1% (95% CI 50-64). Among 
co-infected patients, the rate was 51.4% (36/70) and among 
mono-infected ones, it was 60.5% (69/114) (p=0.241). 
Among patients with cirrhosis, SVR was observed in a 
total of 22 patients, and 18 out of 35 (51.4%; 95% CI 
34-68) were mono-infected and 4 out of 14 (28.6%; 95% 
CI 8.4-58.1; p=0.146) were co-infected. Nine patients (5%) 
were considered non-responders to treatment, in 17 patients 
(9%) the disease relapsed and 2 (1%) presented viral escape. 
To identify factors associated with SVR in patients 
with GEN3 CHC, we tested the relationship between 
this response and each study variable (Table 2). Bivariate 
analysis indicated that the use of Peg-IFN alpha 2b (PR 
0.75; 95% CI 0.58-0.99; p=0.045) and early treatment 
interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; 
p=0.001) were both negatively associated with SVR.
The absence of liver cirrhosis was not significantly 
associated with SVR, although a tendency was observed. 
Among 49 patients with cirrhosis, 22 (44.9%) reached SVR, 
whereas among 130 non-cirrhotic patients, 79 (60.8%) 
reached SVR (PR 0.74; 95% CI 0.53-1.04; p = 0.081) 
(Table 2). The relationship between SVR and liver fibrosis 
stage can also be observed in Figure 1. Among the mono-
infected patients, the treatment duration (24 or 48 weeks) 
was not associated with SVR (p=0-.754). This was also 
observed in patients co-infected with HIV (p=0-.064). 
Among the study population, 34 patients (18.5%) had 
at least one SAE and had to interrupt treatment before 
completion. Early treatment interruption was observed in 20 
(20/114, 17.5%) and 14 (14/70, 20%) patients with mono- 
or co-infection, respectively (PR 1.14; 95% CI 0.62-2.11; 
p=0.677). In all cases, the reason for interruption was an 
SAE (Table 3). 
Table 2 - Distribution of patients with genotype 3 chronic hepatitis C according to clinical and therapeutic characteristics as well 
as sustained virological response (SVR)
Variables Total
SVR
PR  IC 95% (PR) p-value
no %
Sex 0.427
Female 73 39 53.4 0.90 0.69 - 1.17
Agea ... ... ... 0.99 0.98 - 1.00 0.198
HCV/HIV co-infection 0.241
Yes 70 36 51.4 0.85 0.65 - 1.12
Metabolic syndrome 0.479
Yes 36 20 55.6 0.88 0.63 - 1.24
Elevated ALT (n=181) 0.685
Yes 92 51 55.4 0.95 0.74 - 1.22
Fibrosis (n=179) 0.081
4 49 22 44.9 0.74 0.53 - 1.04
Inflammatory activity (n=151) 0.675
3 or 4 38 20 52.6 0.93 0.66 - 1.31
Steatosis (n=148) 0.479
Yes 84 45 53.6 0.90 0.68 - 1.20
Prior treatment (n=182) 0.864
Yes 85 48 56.5 0.98 0.76 - 1.26
Current treatment (n=177) 0.045
Peg IFN 2b 76 37 48.7 0.75 0.58 - 0.99
Adequate Ribavirin dose at the beginning of treatment (n=161) 0.136
Yes 144 84 58.3 1.65 0.85 - 3.20
Adequate Ribavirin dose at the throughout the treatment (n=114) 0.757
Yes 89 53 59.6 1.06 0.72 - 1.57
Early treatment interruption due to severe adverse event 0.001
Yes 34 8 23.5 0.36 0.20 - 0.68
a
 age analyzed as a continuous variable
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Bivariate analysis was used to evaluate a possible 
association between early treatment interruption due to SAE 
and the different evaluated variables. Early interruption was 
associated with age (PR 1.06; 95% CI: 1.02-1.10; p<0.001), 
and liver cirrhosis (PR 2.06; 95% CI: 1.11-3.83; p=0.022) 
(Table 4). The mean age of patients who interrupted their 
treatments before completion was 52.29 (SD 6.778) and 
among those who did not go through early interruptions 
was 47.35 (SD 9.117), (p=0.005). 
Among patients with liver cirrhosis, approximately 30% 
interrupted treatment due to SAEs, while among patients 
with less severe hepatic disease this rate was 15% (p=0.022) 
(Figure 2).
DISCUSSION
In this real-life study including GEN3 CHC patients, 
with or without HIV co-infections, the overall rate of SVR 
was 57.1%, with no differences between mono- (60.5%) 
and co-infected patients (51.4%) (p=0.241). The use of 
Peg-IFN alpha 2b and early treatment interruption due to 
SAE were negatively associated with SVR (p=0.045 and 
p=0.001, respectively). 
Among a study population of 184 patients, 34 (18.5%) 
had at least one SAE and had to interrupt treatment. Such 
early interruptions were associated with age (p<0.001) and 
with the presence of liver cirrhosis (p=0.022).
The overall SVR rate observed here for patients with 
GEN3 corroborates the findings of other authors who used 
combined Peg-IFN/RBV treatment.
When giving the same CHC treatment to co-infected 
patients, several authors have reported higher frequencies of 
SAE, as well as lower SVR rates in comparison with mono-
infected patients14. However, more recently, Monje-Agudo 
et al.15 specifically assessing SVR in GEN3 patients found 
no effect of HIV presence in the attainment of SVR. Much 
like these previous authors, we could not find an effect 
of co-infection by HIV on SVR rates in GEN3 patients. 
It is possible that specific clinical characteristics of our 
population of co-infected individuals contributed to mask 
the effects of HIV on SVR rates. 
According to criteria established by the Brazilian 
Ministry of Health, CHC treatment of co-infected patients 
is recommended for those under stable immunological 
condition. Therefore, it is possible that this condition, which 
was observed for most patients included in our study, may 
partially explain why SVR rates in HIV-HCV patients were 
similar to those observed in mono-infected individuals. This 
pattern may arise from the immunomodulating activity of 
Peg-IFN/RBV, which depends on the immunological status 
of patients16.
Figure 1 - Rate of sustained virologic response obtained with 
Peg-IFN/RBV treatment of patients with Genotype 3 Hepatitis 
C and different degrees of liver fibrosis (F0 to cirrhosis)
Table 3 - Frequency of serious adverse events that resulted in the early interruption of HCV treatment with Peg-IFN/RBV for mono-
infected (HCV) or co-infected (HCV/HIV) patients 
Severe Adverse Event
Mono-infection HCV Co-infection HCV/HIV
p-value
N % N %
Anemia 3 2 5 7 0.145
Thrombocytopenia 5 4 5 7 0.423
Treatment intolerance 2 1 3 4 0.370*
Psychiatric complications 2 1 2 2 0.636*
Cutaneous rash 2 1 0 0 0.526*
Infectious complicationsa 3 2 1 1 >0.999*
Hepatic decompensation 2 1 2 2 0.636*
Decompensation of other comorbiditiesb 2 1 2 2 0.636*
Any severe adverse event 20 18 14 20 0.677
* Fischer exact test. a One case of each of the following conditions: sepsis with pulmonary focus, erysipela, pulmonary abscess, 
opportunistic infection. b Two cases of cardiac decompensation, one case of thyroid decompensation, and one case of chemical 
dependence. 
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Liver cirrhosis is considered an important indicator 
of poor CHC treatment outcome and low SVR rates9,12,15. 
However, this association was not observed in the present 
study, although a non-significant tendency in this direction 
did occur. Among 49 cirrhotic patients, 22 (44.9%) attained 
SVR, whereas 60.8% of non-cirrhotic patients had SVR 
(p = 0.081). We cannot exclude the possibility that the 
number of evaluated patients was just too small to reveal a 
statistically significant association. 
According to our data, the use of Peg-IFN alpha 2a 
was associated with a higher rate of SVR when compared 
with the use of Peg-IFN alpha 2b, in bivariate analysis. 
The superior performance of Peg-IFN alpha 2a in relation 
to Peg-IFN alpha 2b for the treatment of CHC constitutes 
a controversial theme. A few studies have indicated the 
existence of this difference17,18, but a recent systematic 
review could not establish the superiority of either Peg-IFN 
presentation18.
The development of direct-action antiviral agents 
(DAAs) brought about a large increase in SVR rates for 
both mono- and co-infected patients. However, cirrhotic 
Figure 2 - Percentage of patients, with different degrees of 
liver fibrosis (F0 to cirrhosis), who interrupted treatment with 
Peg-IFN/RBV due to serious adverse events
Table 4 - Distribution of patients with genotype 3 chronic hepatitis C according to clinical and therapeutic characteristics as well 
as early treatment interruption 
Variables Total
Early interruption
PR CI 95% (PR) p-value
n %
Sex 0.331
Female 73 16 21.9 1.35 0.74 – 2.48
Agea ... ... ... 1.06 1.02 -1.10 0.001
HCV/HIV co-infection 0.677
Yes 70 14 20.0 1.14 0.62 – 2.11
Metabolic syndrome 0.054
Yes 36 10 27.7 2.17 0.99 – 4.75
Elevated ALT (n=181) 0.395
Yes 92 19 20.6 1.31 0.77 – 2.46
Fibrosis (n=179) 0.022
Grade 4 49 14 28.5 2.06 1.11 – 3.83
Inflammatory activity (n=151) 0.218
Grade 3 or 4 38 9 23.7 1.57 0.76 – 3.24
Steatosis (n=148) 0.379
Yes 84 18 21.4 1.37 0.68 – 2.77
Prior treatment (n=182) 0.739
Yes 85 15 17.6 0.90 0.49 – 1.66
Current treatment (n=177) 0.723
Peg IFN 2b 76 12 15.8 0.89 0.45 – 1.73
Adequate Ribavirin dose at the beginning of treatment (n=161) 0.470
Yes 144 24 16.6 0.71 0.28 – 1.80
Adequate Ribavirin dose at the during treatment (n=114) 0.082
Yes 89 12 13.5 0.48 0.21 – 1.10
a
 age analyzed as a continuous variable
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patients infected by GEN3 genotypes do not respond well 
to the recommended drugs4-6.
In Brazil and in different regions of the world, 
the association of sofosbuvir and daclatasvir is often 
recommended to patients infected with GEN38,19,20. This 
combination treatment usually results in SVR rates ranging 
from 63% to 97%21,22. Some factors have a negative effect 
on the outcome. For example, the presence of liver cirrhosis, 
amount of time on medication, non-adhesion to treatment, 
resistance to NS5A inhibitors and lower SVR rates ranging 
from 25% to 60%21-23. 
In the present study, we observed an overall SVR 
frequency of 57.1%, whereas, among cirrhotic patients, 
this rate was 45%. In patients with less advanced hepatic 
disease, the SVR varied between 59% and 67%. These 
results agree with others, and further support the use of 
Peg-IFN/RBV in patients infected with GEN3, especially 
those who do not have cirrhosis. It is important to note that 
prior use of this combination seems not to select resistant 
viral strains, which otherwise would pose an obstacle to 
patients who do not respond well to therapeutic regimens 
involving proteases or NS5A inhibitors23.
In the current work, 34 (18.5%) patients had at least 
one SAE and had to interrupt treatment before completion. 
Different randomized and real-life studies have identified 
SAE and intolerance to Peg-IFN/RBV as the most important 
indicators of non-adhesion to this therapeutic regimen24,25. 
These authors found treatment interruption rates by 
SAE that were similar to ours, ranging between 8% and 
15%24,25. Interestingly, we did not observe an increase in 
the frequency of SAEs with HIV co-infection. 
As expected, we observed a negative association 
between early treatment interruption by SAE and SVR. 
On the other hand, SAEs were positively associated with 
advancing age and hepatic cirrhosis. The latter has also been 
correlated to treatment interruption by other authors26,27. 
Previous work has also indicated that advancing age is 
associated with worse interferon treatment outcome28. 
The presence of comorbidities, such as depression, and 
the use of injectable drugs have been identified as factors 
that negatively affect responses to Peg-IFN/RBV29. We 
cannot rule out potential contributions of these or other 
comorbidities to the levels of the observed SVR as these 
factors were not analyzed in our study. 
The main limitation of our study arises from intrinsic 
characteristics of its retrospective design. The registration 
bias is an important component of this limitation, because 
data were not collected through a rigid protocol developed 
for the survey. Thus, important variables that could help 
flush out more indicators were left out, such as alcohol 
consumption, BMI, IL-28B polymorphism, HCV viral 
load at the beginning of treatment. We must also mention 
that the study spanned over a period of almost five years, 
during which clinical protocols that guided Peg-IFN/
RBV treatment were slightly altered. Thus, RBV dose 
and duration of treatment underwent some modifications 
expected to occur in real-life studies. In any case, the 
guidelines of the Brazilian Health Ministry have always 
being followed, ensuring a good level of homogenization 
of the treatment received by patients. 
Another limitation of retrospective studies like ours 
is the fact that in this type of study, it is not possible to 
determine how many patients with chronic genotype 3 
HCV infection and treatment indication have been initially 
considered eligible for treatment, or refused treatment. We 
cannot exclude the possibility that the patients selected for 
treatment and with a higher likelihood of achieving SVR 
were included in our analysis. 
In relation to the monitoring of adherence to treatment, 
it was not possible to access this information because of the 
retrospective nature of this study. Conversely, for evaluation 
of the treatment effectiveness in clinical practice, real-life 
studies offer the advantage of eliminating the potential 
bias of a change in behavior and conduct that might occur 
during the execution of a prospective study. Therefore, 
the retrospective nature of our study could somehow be 
advantageous because it provides a real assessment of the 
effectiveness of this type of therapy in Brazil.
In summary, the overall SVR rate was similar to 
previously published values from other real-life studies, 
and co-infection with HIV did not alter the odds of SVR 
or the frequency of SAEs. The rate of therapeutic success 
for these patients infected by GEN3 was fairly satisfactory. 
This finding indicates, that even now when better treatment 
options are available (or in settings where DAAs are not 
available8), the use of Peg-IFN/RBV represents a viable 
course of treatment for GEN3/CHC, especially for young 
patients without more advanced liver disease. Patients 
within this profile also have a lower risk of SAEs and 
treatment interruption. It is also important to mention 
that the use of this regimen is not associated with the 
emergence of resistant viral strains in non-responders. 
Taking these characteristics into consideration, the use 
of Peg-IFN/RBV would be of importance in places where 
the supply of DAAs is limited or restricted to certain 
patient groups. 
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